{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '10.', 'ADMINISTRATIVE MATTERS', 'To comply with ICH GCP or other applicable guidelines, administrative obligations', 'relating to data collection, monitoring, archiving data, audits, confidentiality, ownership,', 'public disclosure requirements and publications must be met.', '10.1.', 'Electronic Case Report Form instructions', 'A validated GSK defined electronic data collection tool will be used as the method for', 'data collection.', 'In all cases, subject initials will not be collected nor transmitted to GSK. Subject data', 'necessary for analysis and reporting will be entered/transmitted into a validated database', 'or data system. Clinical data management will be performed in accordance with', 'applicable GSK standards and data cleaning procedures.', \"While completed eCRFs are reviewed by a GSK Biologicals' Site Monitor at the study\", 'site, omissions or inconsistencies detected by subsequent eCRF review may necessitate', 'clarification or correction of omissions or inconsistencies with documentation and', 'approval by the investigator or appropriately qualified designee. In all cases, the', 'investigator remains accountable for the study data.', 'Once the database is archived and the clinical study report is complete and approved by', 'all parties, each participating investigator will be provided with a CD-ROM of the final', 'version of the data generated at his/her investigational site.', '10.2.', 'Study monitoring by GSK Biologicals', 'GSK will monitor the study to verify that, amongst other items, the:', 'Data are authentic, accurate, and complete.', 'Safety and rights of subjects are being protected.', 'Study is conducted in accordance with the currently approved protocol, any other', 'study agreements, GCP and all applicable regulatory requirements.', 'The investigator and the head of the medical institution (where applicable) agrees to', 'allow the monitor direct access to all relevant documents.', 'The investigator must ensure provision of reasonable time, space and qualified personnel', 'for monitoring visits.', 'Direct access to all study-site related and source data is mandatory for the purpose of', 'monitoring review. The monitor will perform a eCRF review and a Source Document', 'Verification (SDV). By SDV we understand verifying eCRF entries by comparing them', 'with the source data that will be made available by the investigator for this purpose.', 'The Source Documentation Agreement Form describes the source data for the different', 'data in the eCRF. This document should be completed and signed by the site monitor and', '19-OCT-2018', '72', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', \"investigator and should be filed in the investigator's study file. Any data item for which\", 'the eCRF will serve as the source must be identified, agreed and documented in the', 'source documentation agreement form.', 'Upon completion or premature discontinuation of the study, the monitor will conduct site', 'closure activities with the investigator or site staff, as appropriate, in accordance with', 'applicable regulations, GCP, and GSK procedures.', '10.3.', 'Record retention', 'Following closure of the study, the investigator must maintain all site study records', '(except for those required by local regulations to be maintained elsewhere) in a safe and', 'secure location. The records must be easily accessible, when needed (e.g., audit or', 'inspection), and must be available for review in conjunction with assessment of the', 'facility, supporting systems, and staff. Where permitted by applicable laws/regulations or', 'institutional policy, some or all of these records can be maintained in a validated format', 'other than hard copy (e.g., microfiche, scanned, electronic); however, caution needs to be', 'exercised before such action is taken. The investigator must ensure that all reproductions', 'are legible and are a true and accurate copy of the original and meet accessibility and', 'retrieval standards, including re-generating a hard copy, if required. Furthermore, the', 'investigator must ensure that an acceptable back-up of the reproductions exists and that', 'there is an acceptable quality control procedure in place for making these reproductions.', 'GSK will inform the investigator/institution of the time period for retaining these records', 'to comply with all applicable regulatory requirements. The minimum retention time will', 'meet the strictest standard applicable to a particular site, as dictated by ICH GCP or other', 'applicable guidelines, any institutional requirements or applicable laws or regulations, or', 'GSK standards/procedures otherwise, the minimum retention period will default to 25', 'years after completion of the study report.', 'The investigator/institution must notify GSK of any changes in the archival', 'arrangements, including, but not limited to, archival at an off-site facility and transfer of', 'ownership of the records in the event the investigator leaves the site.', '10.4.', 'Quality assurance', 'To ensure compliance with GCP or other applicable guidelines and all applicable', 'regulatory requirements, GSK may conduct a quality assurance audit. Regulatory', 'agencies may also conduct a regulatory inspection of this study. Such audits/inspections', 'can occur at any time during or after completion of the study. If an audit or inspection', 'occurs, the investigator and institution agree to allow the auditor/inspector direct access', 'to all relevant documents and to allocate his/her time and the time of his/her staff to the', 'auditor/inspector to discuss findings and any relevant issues.', '19-OCT-2018', '73', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}